Taris names Duddu president, CEO

> Taris Biomedical has named Sarma Duddu president and CEO and a member of the board of directors, effective immediately. Release

> Amgen has tapped Jonathan Peacock as CFO, effective Sept. 1. Release

> K-V Pharmaceutical has announced that Thomas McHugh has been appointed CFO, effective immediately. Release

> Spectrum Pharmaceuticals has named George Tidmarsh to the position of senior VP, chief scientific officer and head of R&D operations. Release

> Phage Pharmaceuticals has appointed David Jackson to the position of VP, operations planning. Release

> Keryx Biopharmaceuticals has appointed Joseph Feczko to its board of directors. Release

> Seaside Therapeutics has named Marc Beer, former CEO of ViaCell, Karen Dawes, president of Knowledge Decisions, and Steven Paul, former executive VP for science and technology of Eli Lilly, to its board of directors. Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.